Ovarian Cancer Screening Technique Doubles Detection Rates
|
By LabMedica International staff writers Posted on 18 May 2015 |
|
Image: Histopathology of a Brenner tumor, a type of surface epithelial-stromal tumor, which may be benign or malignant, depending on whether the tumor cells invade the surrounding ovarian tissue (Photo courtesy of Nephron).
A risk algorithm using serial biomarker measurements doubles the number of screen-detected ovarian cancers compared to a single threshold rule.
The new screening method involves the interpretation of changes in levels a specific protein associated with ovarian cancer, in women's blood. The conventional ovarian cancer screening method uses a fixed "cut-off" point for the specific protein, meaning that the new method is able to predict a woman's individual risk of developing cancer with greater accuracy.
Scientists at University College London (UK) and their colleagues studied a total of 202,638 post-menopausal women aged 50 and over participated in United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), and were randomly assigned to receive either annual multimodal screening, transvaginal ultrasound or no test at all. They followed up followed up 46,237 women who continued to receive annual multimodal screening. Each participant would have their carcinoma antigen 125 (CA125) levels tested annually over the course of 14 years.
The scientists calculated their risk of ovarian cancer according to the woman's age, their original CA125 levels and how those levels had changed over time. The risk of ovarian cancer was then estimated by comparing the serial pattern with known cases of cancer and controls. Within the group of women receiving multimodal screening, 640 had surgery for suspected cancer. Of these, 133 had invasive epithelial ovarian cancers. Another 22 women were diagnosed with epithelial ovarian cancer within one year of their final annual screen. The team found that found that the new method detected cancer in 86% of women with invasive epithelial ovarian cancer compared with conventional methods used in prior trials or clinical practice that could identify only 41% and 48% respectively. Encouragingly, it ruled out almost 100% of women who were cancer-free. This means these women would not undergo unnecessary further investigation and surgery.
Ian J. Jacobs BA, MA, MBBS, MD, FRCOG, a professor at the University of New South Wales (Sydney, Australia) explained: “CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time. What's normal for one woman may not be so for another. It is the change in levels of this protein that's important.” The study was published on May 4, 2015, in the Journal of Clinical Oncology.
Related Links:
University College London
University of New South Wales
The new screening method involves the interpretation of changes in levels a specific protein associated with ovarian cancer, in women's blood. The conventional ovarian cancer screening method uses a fixed "cut-off" point for the specific protein, meaning that the new method is able to predict a woman's individual risk of developing cancer with greater accuracy.
Scientists at University College London (UK) and their colleagues studied a total of 202,638 post-menopausal women aged 50 and over participated in United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), and were randomly assigned to receive either annual multimodal screening, transvaginal ultrasound or no test at all. They followed up followed up 46,237 women who continued to receive annual multimodal screening. Each participant would have their carcinoma antigen 125 (CA125) levels tested annually over the course of 14 years.
The scientists calculated their risk of ovarian cancer according to the woman's age, their original CA125 levels and how those levels had changed over time. The risk of ovarian cancer was then estimated by comparing the serial pattern with known cases of cancer and controls. Within the group of women receiving multimodal screening, 640 had surgery for suspected cancer. Of these, 133 had invasive epithelial ovarian cancers. Another 22 women were diagnosed with epithelial ovarian cancer within one year of their final annual screen. The team found that found that the new method detected cancer in 86% of women with invasive epithelial ovarian cancer compared with conventional methods used in prior trials or clinical practice that could identify only 41% and 48% respectively. Encouragingly, it ruled out almost 100% of women who were cancer-free. This means these women would not undergo unnecessary further investigation and surgery.
Ian J. Jacobs BA, MA, MBBS, MD, FRCOG, a professor at the University of New South Wales (Sydney, Australia) explained: “CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time. What's normal for one woman may not be so for another. It is the change in levels of this protein that's important.” The study was published on May 4, 2015, in the Journal of Clinical Oncology.
Related Links:
University College London
University of New South Wales
New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Latest Clinical Chem. News
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
Channels
Clinical Chemistry
view channel
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreMolecular Diagnostics
view channel
Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more
Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more.jpeg "Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock)")
First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance... Read more
Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
To improve cancer survival rates, it's crucial to understand the disease during its initial stages. Research involving data from thousands of cancer patients has uncovered exciting findings about how blood... Read moreHematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)")
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read more
.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
Microbiology
view channel
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read moreTechnology
view channel
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
Industry
view channel
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
